MA25404A1 - Methode pour le traitement des desordres neurologiques ou neuropsychiatriques. - Google Patents

Methode pour le traitement des desordres neurologiques ou neuropsychiatriques.

Info

Publication number
MA25404A1
MA25404A1 MA26344A MA26344A MA25404A1 MA 25404 A1 MA25404 A1 MA 25404A1 MA 26344 A MA26344 A MA 26344A MA 26344 A MA26344 A MA 26344A MA 25404 A1 MA25404 A1 MA 25404A1
Authority
MA
Morocco
Prior art keywords
neurological
treatment
neuropsychiatric disorders
neuropsychiatric
disorders
Prior art date
Application number
MA26344A
Other languages
English (en)
Inventor
Lynn Willis Gregory
Original Assignee
Clarencew Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/285,859 external-priority patent/US6310085B1/en
Application filed by Clarencew Pty Ltd filed Critical Clarencew Pty Ltd
Publication of MA25404A1 publication Critical patent/MA25404A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Social Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
MA26344A 1996-10-04 2001-10-01 Methode pour le traitement des desordres neurologiques ou neuropsychiatriques. MA25404A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO2745A AUPO274596A0 (en) 1996-10-04 1996-10-04 Method for the treatment of neurological or neuropsychiatric disorders
US09/285,859 US6310085B1 (en) 1997-10-03 1999-04-02 Method for the treatment of neurological or neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
MA25404A1 true MA25404A1 (fr) 2002-04-01

Family

ID=37945448

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26344A MA25404A1 (fr) 1996-10-04 2001-10-01 Methode pour le traitement des desordres neurologiques ou neuropsychiatriques.

Country Status (21)

Country Link
US (1) US20020068692A1 (fr)
EP (2) EP0964679A4 (fr)
JP (2) JP2001503394A (fr)
CN (1) CN1345238A (fr)
AU (3) AUPO274596A0 (fr)
BG (1) BG106065A (fr)
BR (1) BR0009524A (fr)
CA (2) CA2267381A1 (fr)
CZ (1) CZ20013487A3 (fr)
EE (1) EE200100511A (fr)
HU (1) HUP0200287A3 (fr)
IL (1) IL145696A0 (fr)
MA (1) MA25404A1 (fr)
MX (1) MXPA01009963A (fr)
NO (1) NO20014674L (fr)
NZ (1) NZ515023A (fr)
PL (1) PL350961A1 (fr)
SK (1) SK13862001A3 (fr)
TR (1) TR200102864T2 (fr)
WO (2) WO1998015267A1 (fr)
ZA (1) ZA200108592B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in the prevention and treatment of tardive dyskinesia, pharmaceutical formulations comprising it and its use for the manufacture of medicaments
IL138825A (en) * 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
US7485443B2 (en) 2001-07-17 2009-02-03 Northwestern University Solid-phase reactions
US7303869B2 (en) 2001-07-17 2007-12-04 Northwestern University Solid-phase reactions
JP2005219511A (ja) * 2002-02-05 2005-08-18 Azumaya:Kk ハイジャク防止システムおよぴ防止方法
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
JP5582535B2 (ja) * 2007-06-29 2014-09-03 クラレンス ピーティーワイ エルティーディー 点眼投与による神経疾患または精神神経疾患の治療または予防
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
US10736889B2 (en) * 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
CA2834735C (fr) * 2011-04-29 2021-06-01 University Of Medicine And Dentistry Of New Jersey Utilisation de la nalbuphine pour le traitement de la dyskinesie
US9918980B2 (en) * 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
ES2986033T3 (es) * 2011-05-31 2024-11-08 Clarencew Pty Ltd Métodos para prevenir y tratar afecciones neurológicas relacionadas con la función motora
GB201416017D0 (en) * 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.
CN116354924B (zh) * 2021-12-27 2025-05-30 江苏恩华药业股份有限公司 一种2-咪唑酮衍生物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468391A (en) * 1982-06-25 1984-08-28 Ayerst, Mckenna & Harrison, Inc. Combination of β-adrenoceptor antagonists and anxiolytic agents
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US5283343A (en) * 1987-08-17 1994-02-01 Whitby Research, Inc. 2-aryl substituted N-acetyltryptamines and process of preparing such
US5093352A (en) * 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
WO1991004072A1 (fr) * 1989-09-15 1991-04-04 Donetsky Gosudarstvenny Meditsinsky Institut Imeni M.Gorkogo Dispositif de correction de l'etat emotionnel d'une personne
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5046494A (en) * 1990-08-27 1991-09-10 John Searfoss Phototherapy method
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB2282807A (en) * 1993-10-15 1995-04-19 Merck & Co Inc Tryptophan esters and amides as tachykinin receptor antagonists
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO1998015267A1 (fr) 1998-04-16
CN1345238A (zh) 2002-04-17
CZ20013487A3 (cs) 2003-04-16
BR0009524A (pt) 2002-02-19
CA2366850A1 (fr) 2000-10-12
JP2001503394A (ja) 2001-03-13
AU4372597A (en) 1998-05-05
EE200100511A (et) 2002-12-16
US20020068692A1 (en) 2002-06-06
HUP0200287A3 (en) 2002-12-28
WO2000059504A1 (fr) 2000-10-12
AUPO274596A0 (en) 1996-10-31
TR200102864T2 (tr) 2002-03-21
BG106065A (en) 2002-04-30
AU3410200A (en) 2000-10-23
EP1189613A1 (fr) 2002-03-27
ZA200108592B (en) 2002-10-18
CA2267381A1 (fr) 1998-04-16
NO20014674D0 (no) 2001-09-26
MXPA01009963A (es) 2003-07-14
EP0964679A1 (fr) 1999-12-22
AU736005B2 (en) 2001-07-26
PL350961A1 (en) 2003-02-24
JP2002541105A (ja) 2002-12-03
NO20014674L (no) 2001-09-26
EP0964679A4 (fr) 2002-09-11
NZ515023A (en) 2004-01-30
EP1189613A4 (fr) 2004-02-11
IL145696A0 (en) 2002-06-30
AU782492B2 (en) 2005-08-04
SK13862001A3 (sk) 2003-04-01
HUP0200287A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
MA25404A1 (fr) Methode pour le traitement des desordres neurologiques ou neuropsychiatriques.
DE69737402D1 (de) Vorrichtung zur Behandlung von neurodegenerativen Störungen
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
EP0996456A4 (fr) Procede de traitement des deficits neurologiques
MA26779A1 (fr) Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.
EP0673384A4 (fr) Polypeptides utiles pour traiter des troubles inflammatoires.
EP0876149A4 (fr) Procede de traitement des troubles caracterises par une surexpression de la cytidine-desaminase ou de la desoxycytidine-desaminase
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
FR2652759B1 (fr) Catalyseurs pour le traitement des effluents gazeux et procede de traitement de ces effluents.
MA22649A1 (fr) Procede de preparation de composes pour le traitement des maladies en rapport avec le leucotriene .
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
FR2694575B1 (fr) Procede pour le traitement de revetements en mcralz.
EP0674026A3 (fr) Appareillage pour traitement électrolytique.
EP1039883A4 (fr) Methodes de traitement de maladies liees a l'apolipoproteine e
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
FR2728142B1 (fr) Composition pour le traitement anti-germinatif de tubercules ou de bulbes ; procede de traitement
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
EP0743927A4 (fr) Procede ameliore pour le traitement des eaux usees
EP0860867A4 (fr) Traitement de surface pour micro-usinage
MA24333A1 (fr) Utilisation de 1-hydroxy-2-pyridones pour le traitement de la dermatite seborrheique .
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
EP0672457A3 (fr) Procédé pour le traitement sans résidus des déchets.
FR2755980B1 (fr) Procede pour le traitement thermique de coussinets, en particulier pour des vehicules chenilles et analogues
EP0679397A3 (fr) Utilisation d'amines substituées pour le traitement des insuffisances cérébrales.
FR2719240B1 (fr) Procédé de traitement des suspensions huileuses.